We have a problem in how we talk about aging and memory. The wellness industry has discovered that anxiety about cognitive decline is far more profitable than honest uncertainty. And the incentives are perfectly aligned to keep us worried.
Consider the landscape: magazine covers promise "5 science-backed strategies to boost memory." Clinics offer boutique brain optimization programs. Biohackers livestream their latest cognitive enhancement protocols. Meanwhile, actual neuroscientists will tell you, off the record, that most of what's being sold vastly overstates what we know about preventing dementia in healthy people.
This is not a conspiracy. It is something simpler and more stubborn: an economic system that rewards selling solutions to people who fear aging, while penalizing honest communication about the limits of current science.
The business model depends on three things. First: conflating normal aging with pathology. Forgetting where you put your keys is not early-stage Alzheimer's. But if someone can convince you otherwise, they have a customer. Second: emphasizing individual responsibility. If cognitive health is entirely about your daily choices, then your failure to decline is your fault—and you should buy the fix. Third: targeting affluence. Cognitive anxiety sells best to people with disposable income. A $2,000 annual brain-optimization membership is not marketed to people working multiple jobs.
The research landscape makes this easier. Headlines about "surprising new risk factors for dementia" circulate widely. What circulates less widely is that identifying a risk factor is not the same as identifying something you can modify, or something that affects most people, or something that matters more than the fifty other factors already known. A single study linking one new variable to cognitive outcomes gets repackaged as urgent personal health news. It gets repackaged as a reason to buy something.
Meanwhile, the legitimate interventions—the ones with the strongest evidence—are boring and not very profitable. Sleep matters. Social connection matters. Physical activity matters. Cardiovascular health matters. These things don't generate as much revenue as a proprietary supplement protocol or an exclusive neuroimaging panel.
The people profiting most from cognitive decline anxiety are not primarily your doctors. They are entrepreneurs, supplement makers, wellness coaches, and digital platforms offering brain-training apps. These actors have incentives to be alarmist. Your family physician has incentives to be honest, but they also have fifteen minutes with you and no budget for patient education about nuance.
What should concern us is who this system serves and who it harms. It serves people wealthy enough to afford premium wellness services and anxious enough to pursue them. It harms people who might benefit from evidence-based prevention but can't afford the markup, and it harms people who waste money on interventions with limited evidence. It also harms our collective conversation about aging, which becomes increasingly shaped by marketing rather than science.
None of this means you shouldn't care about cognitive health. You should. The evidence does support that certain lifestyle factors matter. But those factors are available to almost everyone, and they do not require expensive intermediaries.
What you should notice is who benefits when aging is reframed as a crisis that requires purchasing solutions. Ask whether the person selling you cognitive enhancement has incentives to overstate certainty. Ask what they earn if you buy their product. Ask what the actual evidence says versus what the marketing says.
Aging involves real challenges, including real risk of cognitive decline for some people. But that seriousness is precisely why we should resist the wellness industry's preferred narrative: that aging is a personal failure you can purchase your way out of. It's a lucrative narrative. But it's not true.